skip to Main Content

Luminex xMAP® Based Assays

The Luminex technology combines advanced fluidics, optics, and digital signal processing with proprietary microsphere (“bead”) xMAP Technology. This enables a high degree of multiplexing within a single sample volume. The open-architecture of the technology has permitted manufacturers to generate multiplex assay kits for many types of applications. Using the easily configurable xMAP Technology we can develop custom assays that are accurate and cost-effective.

Solution-phase multiplex assays offer the following benefits:

  • Reduced sample volume and other redundant consumables
  • More data from the same amount of labor
  • Faster results due to solution-phase kinetics

The figure below shows the results of an analysis for antibodies to specific bacterial toxins from a single serum sample. Various bacterial toxins were conjugated to color coded microspheres.  The serum sample was incubated at various dilutions with beads in a 96-well plate. Beads were washed and then incubated with the detection antibody. Beads were washed and read on the  Luminex 200 and the data was analyzed using a 4PL fit.


We are using the Luminex® 200™ analyzer

*Luminex and Luminex 200 are registered trademarks of Luminex Corporation

MSD Based Assays

Using a highly sensitive electrochemiluminesence technology developed by Meso Scale Discovery™ (MSD), IBT Bioservices offers custom services for testing cytokines, chemokines and other biomarkers in culture supernatants and sera. We can test using any panel, species, or analyte that MSD offers.

MSD is a revolutionary technology that utilizes electrochemiluminescence detection to detect binding events on patterned arrays. The combination forms a unique solution offering sensitivity, dynamic range and convenience. MSD based assays have a wide dynamic range typically from 10ˆ3 to 10ˆ4 allowing quantitative measurements with high accuracy and without the need for running multiple dilutions. MSD assays can be also established in a multiplex format with 5-10 antigens per well.

  • Capture: 10-100 fold increase in capture capacity compared to ELISA
  • Dynamic Range: 3-4 log dynamic range vs. 1-1.5 log range for ELISA
  • Sensitivity: Detection of analytes at sub-picogram levels
  • Reduced Sample Volume: 5-25 ul volume vs. 50-100 ul for ELISA
  • Speed: The entire assay can be performed in 3 hours
  • Multiplex Capability: Simultaneous measurements for up to 10 analytes


Back To Top
×Close search
Fig. 1 Survival after challenge with INFV H1N1 A/Pert/261/2009 (Tamiflu-resistant strain). Inoculum 1xLD90=1.0E+05 PFU/mouse
Survival after challenge with INFV H1N1 A/Pert/261/2009 (Tamiflu-resistant strain) 1.0E+05 PFU/mouse
Survival and weight change in BALB/c mice challenged with INFV A/ Texas/36/91 (H1N1) and treated with antiviral Osletamivir Phosphate (Tamiflu)
Lung viral load and Survival (30 % weight loss cut-off) in BALB/c mice challenged with INFV H3N2 A/HK/1/68.

Alpha (UK) – B. 1.1.7 / 501Y.V1

amino acid mutations: del69–70 HV, del144 Y, N501Y, A570D, D614G, P681H, T761I, S982A, D1118H

Beta (South Africa) – B.1.351

amino acid mutations: K417N, E484K, N501Y, D614G, A701V

Gamma (Brazil) – P.1

amino acid mutations: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I

Epsilon (Ca, USA) B.1.427

amino acid mutations: L452R, D614G

SARS-CoV-2 Parental Strain Wild Type (Wuhan)
SARS-CoV-2 D614G Variant

amino acid mutations: D614G

Epsilon (Ca, USA) B.1.429

amino acid mutations: S13I, W152C, L452R, D614G

SARS-CoV-2 Delta Variant

amino acid mutations: L452R, E484Q